Arenas R, Juárez-Durán ER

Language: Spanish
References: 13
Page: 357-361
PDF size: 246.09 Kb.

ABSTRACT

Thiamidol is an inhibitor of human tyrosinase and it has been used successfully in humans with melasma. We report a personal experience in 11 Mexican mestizo patients with melasma area and severity index (MASI), 100:2, 90:1, 70:1 and 60:7. Ten cases presented important improvement, and in four of them very important improvement was noticed, and only one presented slight improvement and local irritation.

REFERENCES

1. Ogbechie-Godec OA y Elbuluk N, Melasma: an up-to-date comprehensivereview, Dermatol Ther 2017; 7(3):305-18.

2. Sarkar R, Ailawadi P y Garg S, Melasma in men: a review ofclinical, etiological, and management issues, J Clin AestheticDermatol 2018; 11:53-9.

3. Mann T, Gerwat W, Batzer J et al., Inhibition of human tyrosinaserequires molecular motifs distinctively different from mushroomtyrosinase, J Invest Dermatol 2018; 138(7):1601-8.

4. Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T yKolbe L, Effective tyrosinase inhibition by thiamidol results insignificant improvement of mild to moderate melasma, J InvestDermatol 2019; 139(8):1691-8.e6.

5. Roggenkamp D, Sammain A, Fürstenau M, Kausch M, PasseronT y Kolbe L, Thiamidol® in moderate-to-severe melasma:24-week, randomized, double-blind, vehicle-controlled clinicalstudy with subsequent regression phase, J Dermatol 2021;48(12):1871-6.

6. Platsidaki E, Efstathiou V, Markantoni V et al., Self-esteem, depression,anxiety and quality of life in patients with melasmaliving in a sunny Mediterranean area: results from a prospectivecross-sectional study, Dermatol Ther 2023; 13(5):1127-36.

7. Chaudhary S, Dayal S. Efficacy of combination of glycolic acidpeeling with topical regimen in treatment of melasma, J DrugsDermatol 2013; 12(10):1149-53.

8. Lim JTE, Treatment of melasma using kojic acid in a gel containinghydroquinone and glycolic acid, Dermatol Surg 1999;25(4):282-4.

9. Ebrahim HM, Said Abdelshafy A, Khattab F y Gharib K, Tranexamicacid for melasma treatment: a split-face study, DermatolSurg 2020; 46(11):e102-7.

10. Vargas F, Valdez P y Arenas R, La ocronosis exógena: ¿Qué tantola diagnosticamos o la diferenciamos del melasma?, DermatologíaCMQ 2012; 10(2):143-7.

11. Bertold C, Fontas E, Singh T, Gastaut N, Ruitort S, WehrlenPugliese S y Passeron T, Efficacy and safety of a novel triplecombination cream compared to Kligman’s trio for melasma: A24-week double-blind prospective randomized controlled trial, JEur Acad Dermatol Venereol 2023; 37:2601-7.

12. Philipp-Dormston WG, Vila Echagüe A, Pérez Damonte SH etal., Thiamidol containing treatment regimens in facial hyperpigmentation:an international multi-centre approach consisting ofa double-blind, controlled, split-face study and of an open-label,real-world study, Int J Cosmet Sci 2020; 42(4):377-87.

13. Wolfgang G, Melasma: a step-by-step approach towards a multimodalcombination therapy, Clin Cosmet Investig Dermatol2024; 17:1203-121.